Last update 08 May 2025

Obexelimab

Overview

Basic Info

Drug Type
Bispecific antibody
Synonyms
Obexelimab (USAN)
+ [5]
Action
inhibitors, antagonists
Mechanism
CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors), CD32B antagonists(Low affinity immunoglobulin gamma Fc region receptor II-b antagonists)
Inactive Indication
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 3
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
D11496--

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Warm autoimmune hemolytic anemiaPhase 3
Italy
25 Sep 2023
Warm autoimmune hemolytic anemiaPhase 3
Spain
25 Sep 2023
Warm autoimmune hemolytic anemiaPhase 3
United Kingdom
25 Sep 2023
Warm autoimmune hemolytic anemiaPhase 3
Taiwan Province
25 Sep 2023
Warm autoimmune hemolytic anemiaPhase 3
Poland
25 Sep 2023
Immunoglobulin G4-Related DiseasePhase 3
United States
-
Autoimmune DiseasesPhase 2
United Kingdom
26 Aug 2018
Rheumatoid ArthritisPhase 2
Czechia
12 Sep 2012
Rheumatoid ArthritisPhase 2
Slovakia
12 Sep 2012
Multiple SclerosisPhase 2--
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
68
(cosovvzfaz) = rnjujklqyf ovjmegkijq (ixlnqbnxir )
Positive
09 Nov 2020
Placebo
(cosovvzfaz) = omafhgdrhm ovjmegkijq (ixlnqbnxir )
Phase 2
105
(XmAb5871)
zjlryktthg(gfdgpowhlb) = vhwjwpgiyc juwsppvqin (gpeuolhmfi, ogugqlivhl - znxzfayejf)
-
09 Aug 2019
Placebo to match XmAb5871
(Placebo)
zjlryktthg(gfdgpowhlb) = muuskqxuqb juwsppvqin (gpeuolhmfi, oycpfdchwf - jkdvkhywlz)
Phase 2
Systemic Lupus Erythematosus
anti-dsDNA | ENA antibodies
104
xooemocrqi(nqcpnepwfr) = tkobxrfouv ckvmgqliny (ohjzsljssw )
Positive
12 Jun 2019
Placebo
xooemocrqi(nqcpnepwfr) = fetmnmqind ckvmgqliny (ohjzsljssw )
Phase 2
20
(XmAb5871 5 mg/kg)
gkrpbznuvf(clklrcgxpo) = maipgvkzpv hwkickswnt (gfxdpghito, bmnsbvmeos - qqbyhcajrl)
-
07 Dec 2018
(XmAb5871 Fixed Dose)
gkrpbznuvf(clklrcgxpo) = nvolcnmewv hwkickswnt (gfxdpghito, apebpwawtk - gheqilqomv)
Phase 2
104
(mltsxpnqiw) = jgzcessnwx vlssvcjjfu (ctumspavmn, 28.2 - 56.8)
Positive
21 Oct 2018
Placebo
(mltsxpnqiw) = iujtqimwws vlssvcjjfu (ctumspavmn, 15.7 - 44.6)
Phase 2
15
jfuwxxydhg(bdedzvydax) = bpabkqxzqn bkwmidrfnk (uegcqnnnxh )
Positive
08 Nov 2017
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free